Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 9, 2005
Last updated: August 6, 2012
Last verified: August 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2009
  Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)